Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot phase I trial studies the side effects and best way to give sirolimus, gemcitabine hydrochloride, and cisplatin in treating patients at high risk for cholangiocarcinoma recurrence after liver transplant or surgery. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sirolimus with gemcitabine hydrochloride and cisplatin may prevent disease recurrence in patients with a high risk of recurrence after a liver transplant or surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

NCT03579771

Resectable Cholangiocarcinoma Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 Stage II Intrahepatic Cholangiocarcinoma AJCC v8 +3 more

COMPLETED PHASE2

A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma

NCT02256982

Unresectable Intrahepatic Cholangiocarcinoma Resectable Intrahepatic Cholangiocarcinoma

TERMINATED NA

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

NCT02392637

Stage III Intrahepatic Cholangiocarcinoma AJCC v7 Stage IIIA Gallbladder Cancer AJCC v7 Stage IIIB Gallbladder Cancer AJCC v7 +6 more

COMPLETED PHASE2

Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer

NCT00123825

Gallbladder Cancer Biliary Tract Cancer

COMPLETED PHASE2

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

NCT04088188

Advanced Cholangiocarcinoma Metastatic Cholangiocarcinoma Unresectable Cholangiocarcinoma

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Assessment of the percentage of patients who are able to complete therapy through 4 and 6 months post-registration.

SECONDARY OBJECTIVES:

I. To describe the adverse events, rate of dose reductions, and quality of life in these patients.

II. To summarize timed endpoints of time-to-recurrence, disease-free survival, overall survival, time to treatment failure, and time until treatment related grade 3+ adverse events.

OUTLINE:

Patients receive cisplatin intravenously (IV) over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and sirolimus orally (PO) daily or three times weekly. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for up to 5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)

Patients receive cisplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and sirolimus PO daily or three times weekly. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

Cisplatin

Intervention Type DRUG

Given IV

Gemcitabine Hydrochloride

Intervention Type DRUG

Given IV

Quality-of-Life Assessment

Intervention Type OTHER

Ancillary studies

Sirolimus

Intervention Type DRUG

Given PO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cisplatin

Given IV

Intervention Type DRUG

Gemcitabine Hydrochloride

Given IV

Intervention Type DRUG

Quality-of-Life Assessment

Ancillary studies

Intervention Type OTHER

Sirolimus

Given PO

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Abiplatin Blastolem Briplatin CDDP Cis-diammine-dichloroplatinum Cis-diamminedichloridoplatinum Cis-diamminedichloro Platinum (II) Cis-diamminedichloroplatinum Cis-dichloroammine Platinum (II) Cis-platinous Diamine Dichloride Cis-platinum Cis-platinum II Cis-platinum II Diamine Dichloride Cismaplat Cisplatina Cisplatinum Cisplatyl Citoplatino Citosin Cysplatyna DDP Lederplatin Metaplatin Neoplatin Peyrone's Chloride Peyrone's Salt Placis Plastistil Platamine Platiblastin Platiblastin-S Platinex Platinol Platinol- AQ Platinol-AQ Platinol-AQ VHA Plus Platinoxan Platinum Platinum Diamminodichloride Platiran Platistin Platosin dFdCyd Difluorodeoxycytidine Hydrochloride Gemzar LY-188011 Quality of Life Assessment AY 22989 RAPA Rapamune RAPAMYCIN SILA 9268A WY-090217

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologic proof of presence of residual tumor in liver explants and /or positive resection margins
* Absolute neutrophil count (ANC) \>= 1500/μL obtained =\< 7 days prior to registration
* Platelets (PLT) \>= 100,000/μL obtained =\< 7 days prior to registration
* Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) obtained =\< 7 days prior to registration
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x ULN obtained =\< 7 days prior to registration (=\< 5 x ULN in patients with liver metastases)
* Creatinine =\< 1.5 x Institutional ULN obtained =\< 7 days prior to registration
* Alkaline phosphatase =\< 5 x institutional ULN obtained =\< 7 days prior to registration
* Hemoglobin (Hgb) \>= 9.0 g/dL obtained =\< 7 days prior to registration
* International normalized ratio (INR) and partial thromboplastin (PTT) =\< 3.0 x ULN (anticoagulation is allowed if target INR =\< 3.0 x ULN on a stable dose of warfarin or on a stable dose of low molecular weight \[LMW\] heparin for \> 2 weeks at time of registration)
* Fasting serum glucose \< 1.5 x ULN obtained =\< 7 days prior to registration
* Fasting serum cholesterol =\< 300 mg/dL OR =\< 7.75 mmol/L AND fasting triglycerides =\< 2.5 x ULN obtained =\< 90 days prior to registration; NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
* Ability to provide informed consent
* Willingness to return to Mayo Clinic for follow up
* Life expectancy \>= 12 months
* Women of childbearing potential only: negative serum pregnancy test done =\< 7 days prior to registration
* Four months post liver transplant

Exclusion Criteria

* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Clinically significant cardiac disease, especially history of myocardial infarction =\< 6 months, or congestive heart failure (New York Heart Association \[NYHA\] classification III or IV) requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
* Taking strong inhibitors or strong/moderate inducers of cytochrome P450 (CYP)3A4

* Strong inhibitors of CYP3A4/5; \> 5-fold increase in the plasma area under the curve (AUC) values or more than 80% decrease in clearance

* Clarithromycin (Biaxin®, Biaxin XL®)
* Conivaptan (Vaprisol®)
* Grapefruit juice
* Itraconazole (Sporanox®)
* Ketoconazole (Nizoral®)
* Mibefradil
* Nefazodone (Serzone®)
* Posaconazole (Noxafil®)
* Telaprevir (Incivek®)
* Telithromycin (Ketek®)
* Use of the following inducers are prohibited =\< 7 days prior to registration

* Strong inducers of CYP3A4/5; \> 80% decrease in AUC

* Avasimibe
* Carbamazepine (Carbatrol®, Epitol®, Equetro™, Tegretol®, Tegretol-XR®)
* Phenytoin (Dilantin®, Phenytek®)
* Rifampin (Rifadin®)
* St. John's wort
* Moderate inducers of CYP3A4/5; 50-80% decrease in AUC

* Bosentan (Tracleer®)
* Modafinil (Provigil®)
* Nafcillin
* Phenobarbital (Luminal®)
* Rifabutin (Mycobutin®)
* Troglitazone
* Any of the following prior therapies:

* Chemotherapy =\< 4 weeks prior to registration
* Mitomycin C/nitrosoureas =\< 6 weeks prior to registration
* Immunotherapy =\< 4 weeks prior to registration
* Biologic therapy =\< 4 weeks prior to registration
* Radiation therapy =\< 4 weeks prior to registration
* Radiation to \> 25% of bone marrow prior to registration
* Failure to fully recover from acute, reversible effects of prior surgery or chemotherapy regardless of interval since last treatment
* Any of the following because this study involves cytotoxic agents

* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception
* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration \[FDA\]-approved indication and in the context of a research investigation)
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive with low cluster of differentiation (CD)4 count; Note: previous calcineurin inhibitor or previous sirolimus use allowed
* Current active other malignancy, except non-melanoma skin cancer or carcinoma-in-situ of the cervix; if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
* Current impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of sirolimus (e.g., active ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
* Current severely impaired lung function (i.e., forced expiratory volume in 1 second \[FEV1\] \< 1 liter)
* Received immunization with attenuated live vaccines =\< 7 days prior to study entry or during study period; NOTE: Close contact with those who have received attenuated live vaccines should be avoided during treatment with sirolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guérin (BCG), yellow fever, varicella and typhoid (TY)21a typhoid vaccines
* Current severe hepatic impairment; Note: A detailed assessment of hepatitis B/C medical history and risk factors must be done at screening for all patients; hepatitis B virus (HBV) deoxyribonucleic acid (DNA) and hepatitis C virus (HCV) ribonucleic acid (RNA) polymerase chain reaction (PCR) testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No